Skip to content

A prospective real-world study of the efficacy and safety of the myopic amblyopia comprehensive treatment instrument in controlling mild to moderate myopia in children and adolescents

A prospective real-world study of the efficacy and safety of the myopic amblyopia comprehensive treatment instrument in controlling mild to moderate myopia in children and adolescents

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064335
Enrollment
Unknown
Registered
2022-10-02
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children and adolescents have mild to moderate myopia

Interventions

NA:NA

Sponsors

Hainan Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. The age at enrollment was >= 6 years old and <18 years old; 2. The patient was diagnosed as myopic according to the Guidelines for Prevention and Treatment of Myopia issued by the General Office of the National Health Commission (Medical Letter [2018] No. 393); 3. Optometry after cycloplegia in both eyes -6.00D < SE<= -0.75D; 4. Diopter deviation <1.5 days; 5. Use myopic amblyopia therapeutic instrument (model: BBL2020-01, hereinafter referred to as therapeutic instrument) to control myopia; 6. The subject and his/her guardian can understand the purpose of this study and sign the informed consent. The subject can cooperate with the treatment and related ophthalmic examination.

Exclusion criteria

Exclusion criteria: 1. Strabismus and/or amblyopia; 2. Tumor, heart disease, hypertension, epilepsy, etc.; 3. Use of implantable electronic devices (e.g., pacemakers); 4. Photophobia or inability to open eyes normally due to keratitis, trichiasis, trauma, etc.; 5. Subjects with systemic diseases: history of immune system diseases, central nervous system diseases, Down syndrome, asthma, severe cardiopulmonary function, severe liver and kidney dysfunction; 6. Use atropine at the same time; 7. Suffer from eye diseases that affect vision or refractive error (such as cataract and other lens damage diseases, glaucoma, macular disease, keratopathy, pigmentosis, retinal detachment, severe vitreous opacity, etc.); 8. For internal or external use of photosensitive drugs, photosensitive diseases, solar dermatitis, mentally unhealthy subjects, pregnant women, etc.; 9. The therapeutic apparatus is not applicable after evaluation by the researcher.

Design outcomes

Primary

MeasureTime frame
Axial length change from baseline at 1, 3, 6, and 12 months;

Secondary

MeasureTime frame
Change from baseline in diopter (computerized and subjective optometry) at 1, 3, 6, and 12 months;Change in choroidal thickness from baseline at 1, 3, 6, and 12 months;

Countries

China

Contacts

Public ContactXingwu Zhong

Hainan Eye Hospital

xingzh88@hotmail.com+86 13648600586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026